Precision medicine in Hepatocellular Cancer
Research type
Research Study
Full title
Molecular markers to enable precision medicine in Hepatocellular Cancer
IRAS ID
198951
Contact name
R Sharma
Contact email
Sponsor organisation
Imperial College London
Eudract number
n/a
ISRCTN Number
n/a
Clinicaltrials.gov Identifier
n/a
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
Predicting the clinical course of the disease is of paramount importance in the management of hepatocellular (and other) cancers. It is felt that by investigating the molecular signature of cancer clinicians may prescribe treatments which are more likely to show benefit. This concept is particularly important for liver cancer, where Sorafenib, a multikinase inhibitor, is the only drug currently licensed for advanced hepatocellular carcinoma. Exploring the mechanisms of resistance to this drug is important i) because it provides information on design of agents to over come resistance ii) it may facilitate development of biomarkers which predict whether individual cancers are, or are likely to become, resistant to sorafenib. In the proposed study, we shall investigate genes which may give information on the patient's prognosis and, in a subset of advanced HCC patients, in mediating resistance to sorafenib. These genes will be analysed in the tumor tissue and in peripheral blood both at the DNA level (cancer cell DNA can be detected circulating in the peripheral blood of patients) and as proteins.
REC name
Yorkshire & The Humber - Sheffield Research Ethics Committee
REC reference
17/YH/0015
Date of REC Opinion
25 Jan 2017
REC opinion
Favourable Opinion